Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study

Abstract Background Famitinib is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Previous studies have demonstrated anti-tumour activities of famitinib aga...

Full description

Bibliographic Details
Main Authors: Qiuyan Chen, Linquan Tang, Na Liu, Feng Han, Ling Guo, Shanshan Guo, Jianwei Wang, Huai Liu, Yanfang Ye, Lu Zhang, Liting Liu, Pan Wang, Yingqin Li, Qingmei He, Xiaoqun Yang, Qingnan Tang, Yang Li, YuJing Liang, XueSong Sun, Chuanmiao Xie, Yunxian Mo, Ying Guo, Rui Sun, Haoyuan Mo, Kajia Cao, Xiang Guo, Musheng Zeng, Haiqiang Mai, Jun Ma
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Cancer Communications
Subjects:
Nasopharyngeal carcinoma
Famitinib
Concurrent chemoradiotherapy
Phase I, dynamic contrast-enhanced ultrasound
Online Access:http://link.springer.com/article/10.1186/s40880-018-0330-z

Internet

http://link.springer.com/article/10.1186/s40880-018-0330-z

Similar Items